Kazia Therapeutics Limited is an Australia-based oncology-focused drug development...Kazia Therapeutics Limited is an Australia-based oncology-focused drug development company. The Company is engaged in pharmaceutical research and development. The Company’s drug candidates are designed to treat diseases such as brain cancer, renal cancer, and liver cancer. The Company’s lead programs include paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of VEGFR3. EVT801 is being developed in patients with advanced cancer. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor.More
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
